Jim Simons 'The Man Who Solved The Market' Sold 3 Healthcare Dividend Payers, But Upped Stake In This One By 153%

Zinger Key Points
  • Simons increased its stake in Eli Lilly by approximately 613,764 shares or 153.1% in the third quarter.
  • Renaissance Technologies decreased its stake in Merck by at least 2.2 million shares or roughly 33% in the third quarter.

Jim Simons is the founder and hedge fund manager of Renaissance Technologies, which currently has a total portfolio value north of $77 billion, per Stock Circle. This hedge fund uses a quantitative strategy in determining its stock trades.

Simons' quantitative approach has had legendary success. Gregory Zuckerman wrote, "The Man Who Solved the Market: How Jim Simons Launched the Quant Revolution," which is a story about how Simons pioneered the era of the algorithm, earning at least $23 billion in doing so. Renaissance Technologies has a ten-year return performance of 128%, although last year it struggled, producing a negative return of 19.01%, according to Stock Circle.

Check out three healthcare stocks Simons trimmed, while expanding an existing position in a fourth. 

See Also: Tiger Global Lost $16 Billion In 4 Months, But Held These 2 Dividend Payers

Gilead Sciences Inc. GILD is offering a dividend yield of 3.50% or $2.92 per share annually, using quarterly payments, with a notable track record of increasing its dividends for six consecutive years. Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C.

Simons sold more than 3.3 million shares, or 25.3% of his stake in Gilead Sciences, over the course of the third quarter.

Merck & Company Inc. MRK is offering a dividend yield of 2.66% or $2.76 per share annually, through quarterly payments, with a stellar track record of increasing its dividends for 11 consecutive years. Merck makes pharmaceutical products to treat a variety of conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections.

Renaissance Technologies decreased its stake in Merck by at least 2.2 million shares, or roughly 33% in the third quarter.

 

Novo Nordisk A/S NVO is offering a dividend yield of 1.03% or $1.16 per share annually, making quarterly payments, with a decent track record of increasing its dividends for three consecutive years. Novo Nordisk is the leading provider of diabetes-care products in the world and has nearly 50% market share by volume of the global insulin market.

 

Renaissance Technologies sold over 2.2 million shares or 13% of its stake in Novo Nordisk during the third quarter, but remains the fund's top owned stock, accounting for 2.2% of the total portfolio

Eli Lilly & Co. LLY is offering a dividend yield of 1.09% or $3.92 per share annually, utilizing quarterly payments, with a strong track record of increasing its dividends for eight consecutive years. Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology.

Simons increased his stake in Eli Lilly by approximately 613,764 shares or 153.1% in the third quarter.

Photo: Courtesy of Graham Leuschke on flickr

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Ex-Date
ticker
name
Dividend
Yield
Announced
Record
Payable
Posted In: Large CapNewsDividendsDividendsHealth CareHedge FundsTrading IdeasGeneralDividend Stocks In Health CareHealthcare SectorJames SimonsPharma StocksQuant LegendRenaissance Technologies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...